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Introduction: Adalimumab is a fully human anti–tumor necrosis factor α (anti-TNFα) monoclonal antibody that
specifically blocks the interaction of TNFα with its receptors. It binds both soluble and transmembrane TNFα.
We hypothesized that blocking these TNFα signals regulates the altered TNFα production in rheumatoid arthritis
(RA) patients.
Methods: We compared, by flow cytometry, Toll-like receptor induction levels of membrane and intracellular
TNFα in monocytes (iTNFα + CD14+ cells) from 12 patients before and after adalimumab treatment with those
from 5 healthy donors.
Results: Before starting the treatment, the percentage of iTNFα+ CD14+ cells in the RA patients was significantly
lower than that in healthy donors (mean ± SEM = 33.16 ± 4.82% vs 66.51 ± 2.4%, P < 0.001). When we added in vitro
TNFα to healthy donor culture cells, levels of iTNFα+ CD14+ cells decreased, suggesting that the TNFα signal was
responsible for the iTNFα+ CD14+ cell downregulation observed in the RA patients. After 2, 6 and 12 adalimumab
injections, we observed significant blocking of membrane and soluble TNFα and a progressive increase in
iTNFα+ CD14+ cells in ten patients with a good to moderate response as defined by the European League
Against Rheumatism (EULAR) criteria. Levels of iTNFα+ CD14+ cells after 12 injections in these 10 patients were
comparable to levels in healthy donors. In two patients, iTNFα+ CD14+ cell upregulation was not observed,
and their EULAR-defined responses had not improved. The first patient developed antiadalimumab antibodies,
explaining why adalimumab was not able to block membrane and soluble TNFα. In the second patient, adalimumab
was discontinued because of adverse effects, which led to a decrease in iTNFα+ CD14+ cells to levels measured
before treatment.
Conclusions: Our findings suggest that adalimumab treatment in RA patients can return iTNFα levels to those of
healthy donors. This effect was not observed in the presence of neutralizing antiadalimumab antibodies.Introduction
Tumor necrosis factor α (TNFα) is a proinflammatory
cytokine produced mainly by activated monocytes, ma-
crophages, T lymphocytes and natural killer (NK) cells. In
target cells, this cytokine plays a key role in apoptosis, cell
survival, immunity and inflammation [1-3]. TNFα is
initially synthesized and expressed as a transmembrane
protein. Its extracellular proportion is released in the form* Correspondence: svidal@santpau.cat
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article, unless otherwise stated.of a soluble 17 kDa molecule when it is cleaved by a me-
talloproteinase TNFα-converting enzyme (TACE) [4].
The level of TNFα in the synovial fluid in rheumatoid
arthritis (RA) is high [5,6]. In the synovia, TNFα contrib-
utes to joint destruction by attracting leukocytes, inducing
inflammatory cytokines, upregulating adhesion molecules
on endothelial cells and activating the synthesis of metal-
loproteinases in synovial macrophages, fibroblasts and
chondrocytes [7-10]. TNFα also plays a role in osteoclastic
bone resorption. It stimulates osteoclastogenesis by differ-
entiating progenitor cells and enhancing the expression of
receptor activator of nuclear factor κB ligand [11].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Baseline characteristics of rheumatoid arthritis
patients treated with adalimumaba
Characteristics Data
Gender (% women) 92.8
Mean age (±SD), yr 56.6 ± 13.6
Mean disease duration (±SD), yr 13.8 ± 11.2
Mean RF + and/or ACPA + (%) 78.6
Mean concomitant methotrexate (%) 64.3
Mean concomitant prednisone (%) 64.3
Mean previous DMARDs, number (range) 3.07 (1 to 5)
Mean ESR, mm/h (±SD) 40.1 ± 23.6
Mean CRP, mg/L (±SD) 15.6 ± 17.8
Mean DAS28-ESR, IU (±SD) 5.05 ± 0.95
aACPA Anticitrullinated peptide antibodies; CRP, C-reactive protein; DAS28-ESR,
Disease Activity Score in 28 joints erythrocyte sedimentation rate; DMARDs,
Disease-modifying arthritis drugs; RF, Rheumatoid factor.
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has become a strategic target in the treatment of RA
patients. Adalimumab is a fully human neutralizing anti-
TNFα monoclonal antibody that specifically blocks the
interaction of TNFα with p55 and p75 cell-surface TNFα
receptors [12]. By blocking TNFα, adalimumab can atte-
nuate cartilage and bone destruction partially through the
downregulation of matrix metalloproteinases [13]. More-
over, adalimumab can reduce acute-phase reactants of
inflammation [14], inflammatory cytokines [10] and adhe-
sion molecules responsible for leukocyte migration [13].
Studies have shown that adalimumab is effective in pre-
venting joint damage in early RA [15] and improving
clinical and laboratory parameters, emphasizing the
pivotal role of TNFα in this pathology. However, not
all RA patients treated with adalimumab show this clinical
response [16].
Although adalimumab has been found to block soluble
and transmembrane TNFα [17], whether adalimumab
can regulate the production of intracellular TNFα (intra-
cellular TNFα) on monocytes is unknown. Our aim in
this study was to determine whether blocking TNFα sig-
nals regulates the TNFα production in patients with RA.
Methods
Samples
Heparinized blood obtained from healthy donors (HDs)
(n = 5), patients with active RA who had never received
biological therapy (n = 12), RA patients in remission or
with low activity who were being treated with metho-
trexate (n = 3) and similar patients treated with inflixi-
mab (n = 3) was collected in BD Vacutainer tubes (BD
Pharmingen, Franklin Lakes, NJ, USA). Diagnosis of RA
was based on the American College of Rheumatology cri-
teria [18]. Disease activity was measured using the Disease
Activity Score in 28 joints erythrocyte sedimentation rate
(DAS28-ESR) [19]. Table 1 shows demographic data, clin-
ical parameters and laboratory values of patients with
active RA who were receiving adalimumab treatment
every 2 weeks. We collected blood from RA patients after
two (4 weeks), six (12 weeks) and twelve (24 weeks) injec-
tions of adalimumab. To determine the effectiveness of
adalimumab treatment, we evaluated clinical improvement
using the European League Against Rheumatism (EULAR)
response criteria [20]. We also collected blood from three
methotrexate-treated RA patients over the course of more
than 3 years (ESR (mean ± SD) = 36.33 ± 16.65 mm/h, C-
reactive protein (CRP) = 18.13 ± 15.15 mg/L) and three
RA patients who had been treated with infliximab for
more than 5 years (ESR = 42 ± 30.34 mm/h, CRP = 9.17 ±
3.32 mg/L). Written informed consent was obtained from
the participants, and ethical approval of the study was
granted by the institutional ethics committee of the Hos-
pital de la Santa Creu i Sant Pau.Determination of intracellular tumor necrosis factor α
production in leukocytes
Whole blood from HDs and RA patients was cultured in
5-ml polypropylene tubes (BD Biosciences, San Jose, CA,
USA) with RPMI 1640 medium, 1 μg/ml lipopolysacchar-
ide (LPS) or 10 μg/ml lipoteichoic acid (LTA) (InvivoGen,
San Diego, CA, USA) in the presence of BD GolgiStop™
Protein Transport Inhibitor (BD Biosciences) for 4 hours.
After culturing, cells were stained with anti-CD14-fluo-
rescein isothiocyanate (anti-CD14-FITC) (ImmunoTools,
Friesoythe, Germany). Samples were fixed and lysed with
FACS Lysing Solution (BD Biosciences) for 10 minutes.
Samples were then permeabilized with phosphate-buffered
saline plus 0.3% saponin. After permeabilization, samples
were washed and stained with anti-TNFα-phycoerythrin
(anti-TNFα-PE) (BioLegend, San Diego, CA, USA). iTNFα
production was analyzed in CD14+ cells and in CD14−
neutrophils and lymphocytes by flow cytometry.Determination of membrane tumor necrosis factor α on
monocytes
Whole blood of HDs and RA patients was cultured in
RPMI 1640 medium, LPS (1 μg/ml) or LTA (10 μg/ml)
in the presence of 25 μl of metalloprotease TNFα–con-
verting enzyme (TACE) inhibitor (Cytognos, Salamanca,
Spain). After 4 hours in culture, cells were stained with
anti-CD14-FITC and anti-TNFα-PE (BioLegend). Sam-
ples were then incubated with 2 ml of QUICKLYSIS™
solution (Cytognos). Membrane TNFα (mTNFα) was
analyzed on CD14+ cells by flow cytometry. Adalimumab
injections blocked mTNFα, and only free mTNFα was de-
tected. When patient serum (and consequently adalimu-
mab) was washed out of Toll-like receptor (TLR) ligand
cultures, mTNFα was detectable (data not shown).
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cultures supernatants
Whole blood of HDs and RA patients was cultured with
medium, LPS (1 μg/ml) or LTA (10 μg/ml) at 5% CO2
and 37°C. After 24 hours in culture, supernatants were
collected. Soluble TNFα levels were determined using a
specific enzyme-linked immunosorbent assay (ELISA) kit
according to the manufacturer’s instructions (BD Biosci-
ences). TNFα was quantified with standard curves, and
the limit of detection was 7.5 pg/ml. Adalimumab injec-
tions blocked soluble TNFα, and only free soluble TNFα
was detected.
Determination of adalimumab levels and antiadalimumab
antibodies in serum
Serum from RA patients was collected and kept at −80°C
until use. Adalimumab levels and antiadalimumab anti-
bodies were determined using a specific ELISA kit accord-
ing to the manufacturer’s instructions (Proteomika, Derio,
Spain). The limit of detection was 0.15 ng/ml for adalimu-
mab and 0.4 AU/ml for antiadalimumab antibodies.
Flow cytometry analysis
iTNFα and mTNFα were analyzed on CD14+ monocytes,
and iTNFα was analyzed in neutrophils and lymphocytes
gated according to forward-scatter and side-scatter para-
meters in CD14− cells using a Beckman Coulter FC500
flow cytometer (Beckman Coulter, Barcelona, Spain). We
calculated the percentages of positive cells (% cells)
and geometric mean fluorescence intensity (GMFI) of
each marker using CXP Software 2.2 (Beckman Coulter).
The integrated geometric mean fluorescence intensity
(iGMFI) was used to determine the amount of mTNFα
produced by CD14+ cells and was calculated by multiply-
ing the percentage of positive cytokine-producing cells by
the GMFI [21].
Statistical analysis
Statistical analyses were performed using paired t-tests,
t-tests and Spearman’s correlation in GraphPad Prism 5
software (GraphPad Software, La Jolla, CA, USA). Data
are presented as mean and ± SEM. P-values <0.05 were
considered statistically significant.
Results
Tumor necrosis factor α production in rheumatoid
arthritis patients
iTNFα and mTNFα levels in CD14+ cells and TNFα
levels in supernatants of LPS (TLR4 ligand) and LTA
(TLR2 ligand) of HDs were compared with those of RA
patients. For this purpose, whole-blood cells obtained
from HDs and RA patients were cultured with TLR
ligands before adalimumab therapy was started.HDs showed a higher percentage of iTNFα+ CD14+
cells than RA patients after LPS or LTA culture (LPS
= 66.51 ± 2.4 for HDs vs 33.16 ± 4.82 for RA patients,
P < 0.001; LTA = 39.92 ± 1.42 for HDs vs 17.9 ± 3.4 for RA
patients, P < 0.01) (Figure 1A). TLR ligand–stimulated
neutrophils from HDs showed a higher percentage of
iTNFα+ than those from RA patients (LPS = 0.81 ± 0.15%
for HDs vs 0.35 ± 0.05% for RA patients, P < 0.01; LTA =
0.55 ± 0.1% for HDs vs 0.21 ± 0.03% for RA patients, P <
0.05). HDs and RA patients had a similar percentage of
iTNFα+ lymphocytes (LPS = 0.20 ± 0.04% for HDs vs
020 ± 0.04% for RA patients; LTA = 0.10 ± 0.02% for
HDs vs 0.12 ± 0.02% for RA patients).
The percentages of mTNFα+CD14+ cells and the levels
of supernatant TNFα in RA patients did not differ from
those of HDs after TLR ligand cultures (Figure 1B to D).
Intracellular tumor necrosis factor α production in
rheumatoid arthritis patients after adalimumab treatment
We next sought to determine how adalimumab treatment
could modify the percentage of iTNFα in CD14+ mono-
cytes of RA patients. Whole blood from RA patients
collected after 2, 6 and 12 injections of adalimumab was
cultured with TLR ligands, and iTNFα+ CD14+ cell
percentages were determined. Twelve injections of adali-
mumab significantly increased the iTNFα+ CD14+ per-
centages in RA patients up to levels of HDs (33.16 ± 4.82%
for preinjection vs 53.69 ± 23.49% after 12 injections,
P < 0.05) (Figure 2A). Levels of iTNFα+ CD14+ cells
increased after two (48.29 ± 20.45%, P < 0.01) and six
injections (42.01 ± 18.93%, P < 0.05). The kinetics were
similar in LTA cultures (17.91 ± 11.78% for preinjection vs
32.51 ± 21.46% after 12 injections, P < 0.05). A higher per-
centage of iTNFα+ neutrophils was observed after 12
infusions of adalimumab (LPS = 0.74 ± 0.13%, P < 0.05;
LTA = 0.47 ± 0.09%, P < 0.05).
To confirm the adalimumab findings with other com-
parable anti-TNFα treatments, we included RA pa-
tients treated with infliximab. The percentages of iTNFα+
CD14+ cells were comparable in infliximab-treated
patients (71.53 ± 1.53%), in patients treated with adalimu-
mab (60.68 ± 5.87%) and in HDs (66.51 ± 2.4%).
To determine whether the increases in iTNFα+ CD14+
cells observed in the RA patients were due to adalimumab
treatment or a consequence of the remission state, we
analyzed RA patients in methotrexate-induced remission.
Percentages of iTNFα+CD14+ cells in RA patients in
methotrexate-induced remission were significantly lower
than those in RA patients after 12 injections of adalimu-
mab treatment (28.25 ± 10.5% and 60.68 ± 5.87%, respect-
ively, P < 0.05) (Figure 2A). These low percentages of
iTNFα+ CD14+ cells in methotrexate-treated patients


























































Figure 1 Production of tumor necrosis factor α in healthy donors and rheumatoid arthritis patients after lipopolysaccharide and
lipoteichoic acid cultures. Whole blood of healthy donors (HDs) (n = 4) and rheumatoid arthritis (RA) patients (n = 12) collected before
adalimumab treatment was cultured in the presence of lipopolysaccharide (LPS; 1 μg/ml) or lipoteichoic acid (LTA; 10 μg/ml) for 4 hours to
analyze intracellular tumor necrosis factor α–phycoerythrin (iTNFα-PE) and membrane tumor necrosis factor α–phycoerythrin (mTNFα-PE) by flow
cytometry and for 24 hours to analyze levels of TNFα in supernatants by ELISA. (A) iTNFα and (B) mTNFα were analyzed in monocytes from LPS
and LTA cultures gated according to CD14 expression. Levels of TNFα in culture supernatants of LPS (C) and LTA (D) were analyzed in HDs and
RA patients. A t-test was used for statistical analysis.
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rheumatoid arthritis patients in good to moderate
responders to adalimumab
After 12 injections of adalimumab, ESR, CRP and DAS28-
ESR were significantly lower than before the injections (re-
spectively, 21.72 ± 14.83 mm/h, P < 0.05; 2.64 ± 2.22 mg/L,
P < 0.05; and 2.89 ± 0.96 UI, P < 0.001). The percentage of
iTNFα+ CD14+ cells was comparable in HDs and RA
patients with a good to moderate EULAR response
(10 of 12 patients) after 12 injections of adalimumab
(LPS = 60.68 ± 5.87% vs 66.51 ± 2.4%). These patients had
already presented increased percentages of iTNFα+CD14+
cells after two (49.13 ± 7.05%) and six injections (47.91 ±
4.09%) (Figure 2C).
Adalimumab was not effective in two patients. Patient
11 presented a lower percentage of iTNFα+ CD14+ cells
after LPS and LTA cultures (data not shown) at all post-
injection time points than HDs (Figure 2E). Anotherpatient, patient 7, received the third injection after a
4-week delay due to an infection. The patient then pre-
sented adverse effects (allergy), and adalimumab was
discontinued. In this patient, the increased percentage
of iTNFα+ CD14+ cells and higher EULAR-defined
response seen after the first two injections were not
observed after the third injection (Figure 2D). Consistent
with our observations, DAS28 levels and ESR were inver-
sely correlated with the percentage of iTNFα+ CD14+
cells along treatment (DAS28-ESR =R =−0.445, P= 0.0095;
ESR =R= −0.563, P < 0.0001) in good to moderate EULAR-
defined response patients.
Adalimumab levels and antiadalimumab antibodies in
serum of rheumatoid arthritis patients
In view of the findings described above, we next com-
pared adalimumab levels and antiadalimumab antibodies
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Figure 2 Intracellular tumor necrosis factor α production in whole-blood cells from healthy donors and rheumatoid arthritis patients
after adalimumab treatment. Intracellular tumor necrosis factor α (iTNFα) production was analyzed on CD14+ cells in rheumatoid arthritis
(RA) patients before treatment and after 2, 6 and 12 injections of adalimumab. (A) This graph shows the percentage of iTNFα+ CD14+ after
lipopolysaccharide (LPS) culture in patients before and after adalimumab treatment, after methotrexate (MTX) treatment and in healthy donors
(HDs). (B) This representative image of flow cytometry results shows the percentage of iTNFα+ CD14+ cells after LPS and lipoteichoic acid (LTA)
culture in RA patients before and after 12 injections of adalimumab. EULAR, European League Against Rheumatism. (C) This graph shows the
percentage of iTNFα+ CD14+ cells in LPS culture before and after 2, 6 and 12 injections of adalimumab into RA patients with a good to
moderate EULAR-defined response. (D) This graph shows the percentage of iTNFα+ CD14+ cells in LPS culture before and after two and three
injections of adalimumab into patient 7. The two lines in this figure correspond to two missed injections of adalimumab. The dashed line
corresponds to the suppression of adalimumab. (E) This graph shows percentage of iTNFα+ CD14+ cells in LPS culture before and after 2, 6 and
12 injections of adalimumab into patient 11. A paired t-test was used for statistical analysis between RA patients at different time points. A t-test
was used for statistical analysis between RA patients and HDs. *P < 0.05, ***P < 0.001.
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tients with good to moderate EULAR-defined responses
presented therapeutic levels of adalimumab (>1 μg/ml)
[22] after 12 injections and did not have detectable anti-
adalimumab antibody levels in serum (Table 2).
The two patients (patients 7 and 11) who did not show
a EULAR-defined response presented different patterns.
Although patient 7 showed therapeutic levels of adalimu-
mab after two and three injections, therapy was suspended
after the third injection due to allergic reactions. Conse-
quently, at 24 weeks after initiation of treatment (14 weeks
from the last adalimumab injection), adalimumab levels
were undetectable, coinciding with the downregulation of
iTNFα+ CD14+ percentages to levels comparable to those
before treatment. Patient 11 presented no clinical responseto adalimumab at any moment during follow-up, coincid-
ing with undetectable levels of adalimumab in serum after
2, 6 and 12 injections. These undetectable levels of adali-
mumab were a consequence of the high titers of antiadali-
mumab antibodies after the second injection (Table 2). No
patients had detectable levels of adalimumab antibodies in
serum before adalimumab treatment.
Free tumor necrosis factor α levels at the membrane of
monocytes and in the culture supernatants from
rheumatoid arthritis patients
We evaluated the iGMFI of mTNFα on monocytes and
soluble TNFα in TLR ligand culture supernatants after
2, 6 and 12 injections of adalimumab. mTNFα+ CD14+
cell iGMFI decreased after two injections in all patients
Table 2 Adalimumab and antiadalimumab antibody levels in serum of rheumatoid arthritis patientsa
Patient
Adalimumab levels (mg/ml) Antiadalimumab levels (AU/ml) Discontinuation
cause4 wk 12 wk 24 wk 4 wk 12 wk 24 wk
1 n.d. n.d. n.d. n.d. n.d. n.d. –
2 n.d. n.d. n.d. n.d. n.d. n.d. –
3 n.d. n.d. 9.62 n.d. n.d. NG –
4 n.d. n.d. 10.06 n.d. n.d. NG –
5 n.d. n.d. 4.9 n.d. n.d. NG –
6 n.d. n.d. 14.697 n.d. n.d. NG –
8 14 14.4 24.065 NG NG NG –
9 n.d. n.d. 39.409 n.d. n.d. NG –
10 n.d. n.d. n.d. n.d. n.d. n.d. –
12 n.d. n.d. 8 n.d. n.d. NG –
7 7.8 7 NG NG NG NG Allergy
11 NG NG NG 297,268 81,833 2,925 Lack of efficacy
an.d., Not determined; NG, Negative.
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injections (P < 0.01), 293.3 ± 265.8 for six injections,
and 112.1 ± 84.39 for twelve injections (P < 0.05); LTA
= 144.4 ± 43.68 preinjection, 13.79 ± 6.63 for two injec-
tions (P < 0.05), 243.4 ± 210.1 for six injections and 34.14
± 18.27 for twelve injections (P < 0.05)) (Figure 3A and B).
In patient 11, mTNFα+ CD14+ iGMFI levels decreased
after two injections, but increased thereafter to the levels
measured before initiation of treatment. As expected,
iGMFI levels of mTNFα+ on CD14+ cells from RA pa-
tients in remission after infliximab were comparable to
those from RA patients in remission after adalimumab, but
they were significantly different from those of HDs
(41.99 ± 16.28 for infliximab, 20.62 ± 4.02 for adalimu-
mab and 715.4 ± 144.6 for HDs; P < 0.01).
After two injections of adalimumab, levels of free
soluble TNFα significantly decreased in supernatants
of TLR cultures in all but patient 11 (LPS = 1,888 ±
378.5 pg/ml preinjection, 338.7 ± 153.6 pg/ml for two
injections (P < 0.01), 290.5 ± 219.1 pg/ml for six injections
(P < 0.05) and 338.9 ± 155.4 pg/ml for twelve injections
(P < 0.05); LTA = 676.3 ± 257.4 pg/ml preinjection, 202.2 ±
125.4 pg/ml for two injections (P < 0.05), 506.7 ± 488.6 pg/
ml for six injections, and 54.37 ± 28.49 pg/ml for twelve
injections (P < 0.05)) (Figure 3C and D).
Regulation of intracellular tumor necrosis factor α
production by tumor necrosis factor α signaling
We next analyzed how TNFα-TNF receptor signaling
downregulated iTNFα production in CD14+ cells. Over-
night preincubation of whole-blood cells from HDs
with recombinant TNFα (6 ng/ml) decreased the percent-
age of iTNFα+ CD14+ cells in a 4-hour LPS culture(88.87 ± 6.01% for medium culture vs 11.49+2.11 for
TNFα culture; P < 0.01).
To understand the effect of adalimumab on iTNFα
regulation by TNFα signaling, we established two condi-
tions. First, we precultured cells with TNFα plus adali-
mumab (2 μg/ml) overnight before stimulation with LPS
plus adalimumab for 4 hours. Adalimumab restored the
production of iTNFα in CD14+ monocytes to normal
levels (80.59 ± 6.79%). Second, we precultured cells over-
night with TNFα before stimulation with LPS in the
presence of adalimumab for 4 hours. In this case, adali-
mumab was not able to restore iTNFα production in
CD14+ cells (13.91 ± 0.18%). Preculturing cells with
adalimumab did not alter iTNFα+ CD14+ percentages
(Figure 4).
Discussion
Our present findings suggest that, as a result of exposure
to TNFα, cells from patients with active RA had a lower
percentage of iTNFα+ CD14+ cells compared with HDs.
After 12 injections of adalimumab treatment, the per-
centage of iTNFα+ CD14+ cells increased progressively,
reaching levels similar to those of HDs. This effective
adalimumab-induced iTNFα+ CD14+ upregulation was
observed only in RA patients who showed a EULAR-
defined response. After the first two injections, TNFα on
the membrane and in the culture supernatant was effect-
ively blocked by adalimumab in all but one patient, who
developed antiadalimumab antibodies.
TNFα plays a key role in RA physiopathology. How-
ever, we did not expect patients with active RA to have a
lower percentage of iTNFα+CD14+ cells than HDs after










































Figure 4 Intracellular tumor necrosis factor α regulation in
monocytes after tumor necrosis factor α culture overnight.
Whole blood of healthy donors was cultured overnight with tumor
necrosis factor α (TNFα; 6 ng/ml), adalimumab (ADA; 2 μg/ml)
or media. After culturing, whole blood was stimulated with
lipopolysaccharide (LPS) or LPS plus adalimumab for 4 hours. The
percentage of iTNFα+ CD14+ was analyzed. O/n, Overnight. A t-test















































































































Figure 3 Free tumor necrosis factor α levels on membranes of monocytes and culture supernatants from healthy donors and
rheumatoid arthritis patients after adalimumab treatment. Membrane tumor necrosis factor α (mTNFα) levels on monocytes and culture
supernatants were analyzed in rheumatoid arthritis (RA) patients before and after 2, 6 and 12 injections of adalimumab. Graphs show integrated
geometric mean fluorescence intensity (iGMFI) of mTNFα in healthy donors (HDs) and RA patients after lipopolysaccharide (LPS) culture (A) and
lipoteichoic acid (LTA) culture (B). Graphs shows TNFα concentrations (pg/ml) in healthy donors and RA patients at all time points of adalimumab
treatment, after LPS culture (C) and LTA culture (D). A paired t-test was used for statistical analysis between RA patients and number of injections.
A t-test was used for statistical analysis between RA patients and healthy donors. *P < 0.05, **P < 0.01.
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production. To understand this unexpected finding, we
cultured HD cells with exogenous TNFα, which confirmed
that TNFα signals induced negative feedback on iTNFα
production or increased traffic of iTNFα to the mem-
brane. Other authors have previously observed that
TNFα induced tristetrapolin production, which destabi-
lized TNFα mRNA [23]. Our observations therefore sug-
gest that RA cells were exposed to TNFα. However, TNFα
levels were undetectable in serum from these RA patients.
We propose that alternative sources of TNFα for circulat-
ing RA cells could be local soluble or membrane TNFα
[5,24]. On the basis of the results of our present experiments,
we cannot exclude the potential that there are additional
factors involved in the reduction of iTNFα+CD14+ cells.
We observed that ESR and DAS28-ESR were inversely
correlated with the number of iTNFα+ CD14+ cells, sug-
gesting that iTNFα+ CD14+ cells and inflammatory ac-
tivity were robustly associated. We think that the
downregulation of iTNFα+ CD14+ cells percentage was
a regulatory mechanism to control excessive TNFα and
its detrimental consequences.
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symptoms in adult patients with moderately to severely
active RA. It induces clinical response, inhibits the
progression of joint damage and improves physical
function [25]. Here we show that levels of iTNFα+
CD14+ cells increased progressively after the first two
injections of adalimumab. This effect was not observed
in RA patients in remission induced by methotrexate,
suggesting that upregulation of iTNFα+CD14+ cells was
adalimumab-dependent. In addition, the highest levels of
iTNFα+ CD14+ cells after 12 injections coincided with
the greatest clinical improvement (measured by EULAR-
defined response), suggesting that proper regulation of
iTNFα production in RA patients was associated with a
good to moderate EULAR-defined response .
In our in vitro experiments, adalimumab was not able
to restore normal iTNFα+ CD14+ levels overnight when
cells had previously been exposed to TNFα, suggesting
that, in vivo, normalization of iTNFα+ CD14+ cells was
due to indirect mechanisms. One possible mechanism is
that adalimumab blocks TNFα binding to its receptor
[12]. Without TNFα signaling [23], interleukin 1 (IL-1),
IL-6, IL-8, granulocyte-macrophage colony-stimulating
factor [10] and acute-phase reactants of inflammation
(CRP, fibrinogen and ESR) [14] are reduced. This reduc-
tion implicates the return of RA cells to a basal state
similar to that of cells of HDs and the consequent
correction of the percentage of iTNFα+ CD14+ cells.
Another possible mechanism is that the renovated circu-
lating pool of CD14+ cells has no contact with TNFα,
because TNFα is blocked [26]. A third possible mechan-
ism is also worthy of mention. Monocytes and macro-
phages from RA patients are targets of TNFα signals and
the major producing cells of TNFα, which they present
in significant amounts in membrane [27]. Adalimu-
mab has cytotoxic effects on mTNFα-expressing cells
[28]. However, it takes several days to get rid of all
the cells with mTNFα. Once they are all eliminated,
new CD14+ cells with regular iTNFα production repopu-
late the system.
We observed that infliximab, another neutralizing
anti-TNFα monoclonal antibody, restored the percent-
ages of iTNFα+ CD14+ cells to normal values after a
long period of therapy. However, in a previous study
with infliximab, researchers showed that monocytes pro-
duced lower amounts of iTNFα after 24 weeks of treat-
ment than before treatment [29]. This discrepancy in
results could be due to clinical and methodological dif-
ferences. The most crucial difference is that the results
described in the previous report were expressed as mole-
cules of equivalent soluble fluorescein per cell, whereas
ours are expressed as the percentage of CD14+ mono-
cytes with iTNFα. In addition, and in contrast to those
authors, we also evaluated iTNFα levels in HDs toestablish the normal percentages of iTNFα+ CD14 + -pro-
ducing cells.
It should be noted here that, although infliximab and
adalimumab are both TNFα-blocking antibodies, they
are not fully comparable. Infliximab is administered intra-
venously at 0, 2 and 6 weeks, followed by a maintenance
infusion dose every 8 weeks, whereas adalimumab is ad-
ministered subcutaneously every 15 days. Moreover, inflix-
imab is a chimeric antibody, whereas adalimumab is a
fully humanized antibody.
Adalimumab treatments significantly reduced levels of
free mTNFα on CD14+ cells and free soluble TNFα in
TLR cultures compared to the first injection. This dra-
matic reduction in mTNFα on cells was due to two activ-
ities of adalimumab: (1) its binding blocked TNF signals
and (2) it competed with antibodies for flow cytometry
detection [17]. A similar conclusion could be reached for
soluble TNFα [30]. Unfortunately, our experimental ap-
proach does not allow us to establish the fate of mTNFα
and soluble TNFα after adalimumab. However, because
iTNFα is the source of mTNFα and soluble TNFα, we can
speculate that iTNFα, mTNFα and soluble TNFα have
comparable kinetics.
Not all patients respond to adalimumab therapy [16].
In our study, patient 11 did not respond, and, conse-
quently, no iTNFα regulation in CD14+ cells was ob-
served. The lack of response in this patient was due to the
presence of antiadalimumab antibodies after the second
injection. Although patient 7 responded to adalimumab
and iTNFα+ CD14+ cells increased accordingly after
two injections, treatment was discontinued after the
third injection due to allergy. Consequently, the per-
centage of iTNFα+ CD14+ cells dropped to levels seen
before adalimumab therapy was started. We think that, if
adalimumab had not been withdrawn, this patient could
have had a good or moderate EULAR-defined response.
We hope that our ongoing experiments will allow us to
determine whether the increase in iTNFα+CD14+ cells is
RA-specific or could be extended to other inflammatory
pathologies in which TNFα plays a crucial role. Studying
the regulation of iTNFα+CD14+ cells in RA patients
could provide individualized information about the ef-
ficacy of adalimumab treatment.Conclusions
Our findings suggest that adalimumab treatment in RA
patients can return iTNFα levels to those of HDs. This
effect was not observed in the presence of neutralizing
antiadalimumab antibodies that produced no EULAR-
defined response. Our future studies of iTNFα in mono-
cytes during treatment with adalimumab therapy in RA
patients could provide information about the effective-
ness of treatment.
Zamora-Atenza et al. Arthritis Research & Therapy 2014, 16:R153 Page 9 of 10
http://arthritis-research.com/content/16/4/R153Abbreviations
ACPA: Anticitrullinated peptide antibody; CRP: C-reactive protein;
DMARD: Disease-modifying antirheumatic drug; ESR: Erythrocyte
sedimentation rate; HD: Healthy donor; iGMFI: Integrated geometric mean
fluorescence intensity; iTNFα: Intracellular tumor necrosis factor α;
LPS: Lipopolysaccharide; LTA: Lipoteichoic acid; mTNFα: Membrane tumor
necrosis factor α; RA: Rheumatoid arthritis, RF, rheumatoid factor;
TACE: Metalloproteinase tumor necrosis factor α–converting enzyme;
TLR: Toll-like receptor; TNFα: Tumor necrosis factor α.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CZ carried out cell culture and flow cytometry, analyzed and interpreted the
experimental and clinical data, participated in the design of the study and
drafted and edited the manuscript. CDT collected samples and clinical
parameters, analyzed and interpreted the experimental and clinical data and
participated in the design of the study. CG, CDL, JC, JLL and PM collected
samples and clinical parameters. MAO carried out ELISAs and analysis of
data. IC collected samples and clinical parameters and revised several
sections of the manuscript. JCN carried out ELISAs and participated in the
analysis of flow cytometry data.
EC assisted in the cell culture design and analyzed the experimental data.
CJ participated in the analysis of experimental data and revised several
sections of the manuscript. SV conceived of the study, participated in the
design and coordination of the study, analyzed clinical and experimental
data and participated in the drafting and editing of the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
We thank Carolyn Newey for helpful editorial assistance. We thank Maite
Sanz and Immunology laboratory for their technical collaboration. The work
reported has been supported by Abbott Laboratories. SV was supported by
“Fondo Investigaciones Sanitarias” and participant in the Program for
Stabilization of Investigators of the Direcció i d’Estrategia i Coordinació del
Departament Salut de la Generalitat de Catalunya.
Author details
1Department of Immunology, Biomedical Research Institut Sant Pau
(IBB Sant Pau), C. Antoni M. Claret, 167, 08025 Barcelona, Spain. 2Unit of
Rheumatology, Department of Internal Medicine, Hospital de la Santa Creu i
Sant Pau, C. Antoni M. Claret, 167, 08025 Barcelona, Spain. 3Department of
Immunology, Hospital de la Santa Creu i Sant Pau, C. Antoni M. Claret, 167,
08025 Barcelona, Spain.
Received: 23 December 2013 Accepted: 4 July 2014
Published: 18 July 2014
References
1. Bemelmans MH, van Tits LJ, Buurman WA: Tumor necrosis factor: function,
release and clearance. Crit Rev Immunol 1996, 16:1–11.
2. Bazzoni F, Beutler B: The tumor necrosis factor ligand and receptor
families. N Engl J Med 1996, 334:1717–1725.
3. Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor
superfamilies: integrating mammalian biology. Cell 2001, 104:487–501.
4. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner
BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA,
Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP:
A metalloproteinase disintegrin that releases tumour-necrosis factor-α
from cells. Nature 1997, 385:729–733.
5. Matsuno H, Yudoh K, Katayama R, Nakazawa F, Uzuki M, Sawai T,
Yonezawa T, Saeki Y, Panayi GS, Pitzalis C, Kimura T: The role of TNF-α in
the pathogenesis of inflammation and joint destruction in rheumatoid
arthritis (RA): a study using a human RA/SCID mouse chimera.
Rheumatology (Oxford) 2002, 41:329–337.
6. Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C: Tumour necrosis
factor in serum and synovial fluid of patients with active and severe
rheumatoid arthritis. Ann Rheum Dis 1990, 49:665–667.7. Middleton J, Americh L, Gayon R, Julien D, Aguilar L, Amalric F, Girard JP:
Endothelial cell phenotypes in the rheumatoid synovium: activated,
angiogenic, apoptotic and leaky. Arthritis Res Ther 2004, 6:60–72.
8. Connor AM, Mahomed N, Gandhi R, Keystone EC, Berger SA: TNFα
modulates protein degradation pathways in rheumatoid arthritis
synovial fibroblasts. Arthritis Res Ther 2012, 14:R62.
9. Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR:
Macrophages in rheumatoid arthritis. Arthritis Res 2000, 2:189–202.
10. Choy EH, Panayi GS: Cytokine pathways and joint inflammation in
rheumatoid arthritis. N Engl J Med 2001, 344:907–916.
11. OG D, Ireland D, Bord S, Compston JE: Joint erosion in rheumatoid
arthritis: interactions between tumour necrosis factor α, interleukin 1,
and receptor activator of nuclear factor κB ligand (RANKL) regulate
osteoclasts. Ann Rheum Dis 2004, 63:354–359.
12. van de Putte LBA, Salfeld J, Kaymakcalan Z: Adalimumab. In TNF-Inhibition
in the Treatment of Rheumatoid Arthritis. Edited by Moreland LW, Emery P.
London: Martin Dunitz; 2003:93.
13. den Broeder AA, Joosten LA, Saxne T, Heinegard D, Fenner H, Miltenburg
AM, Frasa WL, van Tits LJ, Buurman WA, van Riel PL, van de Putte LB, Barrera
P: Long term anti-tumour necrosis factor α monotherapy in rheumatoid
arthritis: effect on radiological course and prognostic value of markers of
cartilage turnover and endothelial activation. Ann Rheum Dis 2002,
61:311–318.
14. HUMIRA (adalimumab): Summary of Product Characteristics [package insert].
Abbott Park, IL: Abbott Laboratories; 2005.
15. Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T,
Uchida S, Akama H, Kupper H, Arora V, Tanaka Y: Adalimumab, a human
anti-TNF monoclonal antibody, outcome study for the prevention of
joint damage in Japanese patients with early rheumatoid arthritis: the
HOPEFUL 1 study. Ann Rheum Dis 2014, 73:536–543.
16. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L,
Dijkmans BA, Tak PP, Wolbink GJ: Clinical response to adalimumab:
relationship to anti-adalimumab antibodies and serum adalimumab
concentrations in rheumatoid arthritis. Ann Rheum Dis 2007, 66:921–926.
17. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T:
Transmembrane TNF-α: structure, function and interaction with anti-TNF
agents. Rheumatology (Oxford) 2010, 49:1215–1228.
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey
LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt
DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American
Rheumatism Association 1987 revised criteria for the classification of
rheumatoid arthritis. Arthritis Rheum 1988, 31:315–324.
19. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N: Comparison of
Disease Activity Score (DAS)28- erythrocyte sedimentation rate and
DAS28-C-reactive protein threshold values. Ann Rheum Dis 2007, 66:407–409.
20. Fransen J, van Riel PL: The Disease Activity Score and the EULAR
response criteria. Clin Exp Rheumatol 2005, 23:S93–S99.
21. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST,
Andersen P, Reed SG, Morris SL, Roederer M, Seder RA: Multifunctional TH1
cells define a correlate of vaccine-mediated protection against
Leishmania major. Nat Med 2007, 13:843–850.
22. Nestorov I: Clinical pharmacokinetics of TNF antagonists: how do they
differ? Semin Arthritis Rheum 2005, 34:12–18.
23. Carballo E, Lai WS, Blackshear PJ: Feedback inhibition of macrophage tumor
necrosis factor-α production by tristetraprolin. Science 1998, 281:1001–1005.
24. Manicourt DH, Triki R, Fukuda K, Devogelaer JP, Nagant De Deuxchaisnes C,
Thonar EJ: Levels of circulating tumor necrosis factor α and interleukin-6 in
patients with rheumatoid arthritis, Relationship to serum levels of
hyaluronan and antigenic keratan sulfate. Arthritis Rheum 1993, 36:490–499.
25. Mease PJ: Adalimumab in the treatment of arthritis. Ther Clin Risk Manag
2007, 3:133–148.
26. Whitelaw DM: Observations on human monocyte kinetics after pulse
labeling. Cell Tissue Kinet 1972, 5:311–317.
27. Chu CQ, Field M, Feldmann M, Maini RN: Localization of tumor necrosis
factor α in synovial tissues and at the cartilage-pannus junction in
patients with rheumatoid arthritis. Arthritis Rheum 1991, 34:1125–1132.
28. Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A,
To K, Harashima S, Hatta N, Harada M: Mechanisms for cytotoxic effects of
anti-tumor necrosis factor agents on transmembrane tumor necrosis
factor α-expressing cells: comparison among infliximab, etanercept, and
adalimumab. Arthritis Rheum 2008, 58:1248–1257.
Zamora-Atenza et al. Arthritis Research & Therapy 2014, 16:R153 Page 10 of 10
http://arthritis-research.com/content/16/4/R15329. Schuerwegh AJ, Van Offel JF, Stevens WJ, Bridts CH, De Clerck LS:
Influence of therapy with chimeric monoclonal tumour necrosis factor-α
antibodies on intracellular cytokine profiles of T lymphocytes and
monocytes in rheumatoid arthritis patients. Rheumatology (Oxford) 2003,
42:541–548.
30. Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK,
Salfeld J, Sasso EH: Comparisons of affinities, avidities, and complement
activation of adalimumab, infliximab, and etanercept in binding to
soluble and membrane tumor necrosis factor. Clin Immunol 2009,
131:308–316.
doi:10.1186/ar4615
Cite this article as: Zamora-Atenza et al.: Adalimumab regulates
intracellular TNFα production in patients with rheumatoid arthritis.
Arthritis Research & Therapy 2014 16:R153.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
